- Previous Close
3.5400 - Open
3.5400 - Bid --
- Ask --
- Day's Range
3.5400 - 3.5400 - 52 Week Range
2.6200 - 4.3400 - Volume
1,119 - Avg. Volume
0 - Market Cap (intraday)
7.474M - Beta (5Y Monthly) 2.30
- PE Ratio (TTM)
-- - EPS (TTM)
-4.3000 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
www.neurometrix.comRecent News: NLZ0.MU
View MorePerformance Overview: NLZ0.MU
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NLZ0.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NLZ0.MU
View MoreValuation Measures
Market Cap
8.00M
Enterprise Value
-6.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.72
Price/Book (mrq)
0.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-203.71%
Return on Assets (ttm)
-28.21%
Return on Equity (ttm)
-42.78%
Revenue (ttm)
3.77M
Net Income Avi to Common (ttm)
-7.68M
Diluted EPS (ttm)
-4.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
14.83M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--